Changzhou Nrb Corporation Stocks

CN¥ 13.17Last Updated 28.04.2026

Issuer Rating

4/7
Performance

Poor

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.08B

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 13.17
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Changzhou Nrb Corporation engages in the research, development, manufacture, and sale of auto precision bearing products in China and internationally. The company's primary products include needle roller bearings, roller bearings, clutch release bearings, and hub bearings. It also provides hydraulic clutch release, robot, single and double row cylindrical roller, push and pull type clutch release, deep groove ball, joint, and four-point contact ball bearings, as well as synchronizer intermediate ring and large size industrial bearings. It provides its products primarily for application to assemblies, such as automotive transmissions, clutches, heavy truck axles, and hubs. The company was formerly known as Changzhou Guangyang Bearing Co., Ltd. and changed its name to Changzhou Nrb Corporation in May 2014. Changzhou Nrb Corporation was founded in 1994 and is based in Changzhou, China.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks